Emile E Voest
Overview
Explore the profile of Emile E Voest including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
220
Citations
10050
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coelho M, Strauss M, Watterson A, Cooper S, Bhosle S, Illuzzi G, et al.
Nat Genet
. 2024 Oct;
56(11):2479-2492.
PMID: 39424923
Drug resistance is a principal limitation to the long-term efficacy of cancer therapies. Cancer genome sequencing can retrospectively delineate the genetic basis of drug resistance, but this requires large numbers...
2.
Verkerk K, van der Wel T, Zeverijn L, Geurts B, Spiekman I, de Wit G, et al.
Clin Cancer Res
. 2024 Oct;
30(23):5323-5332.
PMID: 39352721
Purpose: To provide patients with MET-mutated advanced non-small cell lung cancer (METmut aNSCLC) access to crizotinib, further substantiate evidence of its efficacy and safety in this setting, and find potential...
3.
Zeverijn L, Geurts B, Battaglia T, van Berge Henegouwen J, de Wit G, Hoes L, et al.
Clin Cancer Res
. 2024 Jul;
30(19):4339-4351.
PMID: 39024037
Purpose: The treatment efficacy of nivolumab was evaluated in patients with advanced, treatment-refractory solid mismatch repair deficiency/microsatellite-instable (dMMR/MSI) tumors, and in-depth biomarker analyses were performed to inform precision immunotherapy approaches....
4.
van Berge Henegouwen J, Zeverijn L, Geurts B, Hoes L, van der Wijngaart H, van der Noort V, et al.
Clin Cancer Res
. 2024 Jun;
30(17):3937-3943.
PMID: 38926908
Purpose: Although eligibility criteria are essential in trial design, overly restrictive criteria contribute to low accrual and limited generalizability. To enhance trial inclusivity, there has been growing interest in broadening...
5.
Chalabi M, Verschoor Y, Tan P, Balduzzi S, Van Lent A, Grootscholten C, et al.
N Engl J Med
. 2024 Jun;
390(21):1949-1958.
PMID: 38838311
Background: Mismatch repair-deficient (dMMR) tumors can be found in 10 to 15% of patients with nonmetastatic colon cancer. In these patients, the efficacy of chemotherapy is limited. The use of...
6.
Tasken K, F Haj Mohammad S, Fagereng G, Falk R, Helland A, Barjesteh van Waalwijk van Doorn-Khosrovani S, et al.
Acta Oncol
. 2024 May;
63:385-391.
PMID: 38779910
Background: In the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials), we aim to...
7.
F Haj Mohammad S, Timmer H, Zeverijn L, Geurts B, Spiekman I, Verkerk K, et al.
Acta Oncol
. 2024 May;
63:368-372.
PMID: 38779868
Background And Purpose: The Drug Rediscovery Protocol (DRUP) is a Dutch, pan-cancer, nonrandomized clinical trial that aims to investigate the efficacy and safety of targeted and immunotherapies outside their registered...
8.
Leek L, Notohardjo J, de Joode K, Velker E, Haanen J, Suijkerbuijk K, et al.
Sci Rep
. 2024 May;
14(1):11244.
PMID: 38755213
We evaluated the prognostic value of hypoalbuminemia in context of various biomarkers at baseline, including clinical, genomic, transcriptomic, and blood-based markers, in patients with metastatic melanoma treated with anti-PD-1 monotherapy...
9.
Geurts B, Zeverijn L, van Berge Henegouwen J, van der Wijngaart H, Hoes L, de Wit G, et al.
J Pathol
. 2024 May;
263(3):288-299.
PMID: 38747304
In the Drug Rediscovery Protocol (DRUP), patients with cancer are treated based on their tumor molecular profile with approved targeted and immunotherapies outside the labeled indication. Importantly, patients undergo a...
10.
Geurts B, Zeverijn L, Leek L, van Berge Henegouwen J, Hoes L, van der Wijngaart H, et al.
Clin Cancer Res
. 2024 Apr;
30(17):3735-3746.
PMID: 38630551
Purpose: To evaluate the efficacy of pembrolizumab across multiple cancer types harboring different levels of whole-genome sequencing-based tumor mutational load (TML; total of nonsynonymous mutations across the genome) in patients...